USP’s Medicine Supply Map is an early-warning system for possible drug shortages, whether due to global health crises, natural disasters, geopolitical events, or quality-related issues in manufacturing. It enhances visibility into the upstream medicines supply chain to help governments, manufacturers, distributors, and providers identify and address vulnerabilities, lessen quality risks, reduce the frequency and duration of potential drug shortages, and protect patients
USP’s Medicine Supply Map leverages insights derived from the use of USP quality standards in more than 22 thousand locations around the world, spanning 92 percent of generic medicines approved in the U.S. It aggregates more than 40 external datasets and 250 million data points to quantify risk and resilience in the upstream pharmaceutical supply chain.
Insights on Supply Chain Vulnerability
Read original analysis about the global distribution of APIs and risks associated with specific drug classes, from broadly used medicines to those that are critically needed in small populations.
Pinpoint supply chain risks
Leveraging multiple data sources, the Medicine Supply Map helps identify, characterize, and quantify risk factors to help guard against over-reliance on over-concentrated sources, reduce disruptions, and build resilience.
Supply resilience scores to address risks
Data analytics shed light on factors that help drive resilience in the pharmaceutical supply chain. Vulnerable populations can be particularly at risk when shortages occur, as with pediatric oncology medicines.